Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Control Bionics Limited

CBL

Control Bionics Ltd. engages in the manufacture, design, and sale of wireless wearable electromyography (EMG) based augmentative and alternative communication (AAC) technology. The company assists patients whose ability to communicate verbally or through text and social media is compromised by illnesses, such as motor neuron disease, amyotrophic lateral sclerosis, and others. Its NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as Electromyography output. This output is then sent wirelessly through the NeuroNode to a personal computer, enabling speech and other computer-controlled functions, such as email and texting. Its core systems include NeuroNode Trilogy, NeuroNode Duo, Eye-gaze Duo, and DROVE. Its technology is integrated with eye-gaze technology, whereby the eye gaze enables a cursor to be moved on a computer screen, driven like a mouse, and the NeuroNode acts like the mouse button.

Vanguard Diversified High Growth Index ETF

VDHG

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.